- Company
- New pulmonary hypertension drugs are competing for approval
- by Moon, sung-ho Aug 11, 2025 06:03am
- Global pharmaceutical companies are introducing new treatment options for pulmonary hypertension, utilizing novel mechanisms, which are being successively approved in the Korean market. These drugs are expected to change the clinical treatment paradigm. It's anticipated that they will establish a new market alongside the currently reimbursed
- Company
- Jaqbo’s substance patent extended to 2040
- by Kim, Jin-Gu Aug 8, 2025 06:03am
- Onconic Therapeutics announced on the 7th that the patent term for Jaqbo (zastaprazan), a new drug for gastroesophageal reflux disease in the P-CAB (potassium-competitive acid blocker class, has been extended by four years and two months. According to the company, the Korean Intellectual Property Office recently extended the patent term o
- Company
- Rapid growth in RSV prevention market for infants
- by Whang, byung-woo Aug 8, 2025 06:02am
- After the COVID-19 pandemic, the importance of preventing infectious diseases has been re-emphasized. A new anti-RSV (Respiratory Syncytial Virus) antibody injection for infants, Beyfortus, is gaining attention as a potential turning point in the vaccine market Korea. Attention has been focused on whether a presidential pledge to support thi
- Company
- Immunosuppressant market rapidly expands in 3yrs in KOR
- by Kim, Jin-Gu Aug 8, 2025 06:02am
- The market for major immunosuppressants such as tacrolimus, cyclosporine, and mycophenolate has rapidly expanded over the past three years. The related market grew relatively slowly at less than 5% until 2022, but since 2023, it has expanded by more than 10% a year, showing a sharp growth trend. The tacrolimus and mycophenolate markets also s
- Company
- Mounjaro set for launch in Korea this month
- by Son, Hyung Min Aug 8, 2025 06:02am
- Eli Lilly Korea's diabetes and obesity treatment, Mounjaro, is set to launch in mid-August. Therefore, it will compete against Novo Nordisk's Wegovy. Lilly plans to handle Mounjaro's distribution directly, a strategy that differentiates it from Novo Nordisk, which is currently seeking co-promotion partners. According to the distribution indus
- Company
- Donepezil ↑8%, memantine 10%↑…replaces choline alfoscerat
- by Kim, Jin-Gu Aug 7, 2025 06:10am
- Sales of donepezil, memantine, and nicergoline-based dementia treatments, which have emerged as alternatives to choline alfoscerate formulations, are growing. In the first half of this year, donepezil’s sales recorded KRW 162.6 billion, an 8% increase from the previous year. Sales of memantine-based formulation increased by 10% year-on
- Company
- Yuhan’s Leclaza to receive ₩100B in milestone payment
- by Chon, Seung-Hyun Aug 7, 2025 06:06am
- With Yuhan Corp’s new anticancer drug Leclaza approved in China, the company announced that it will receive KRW 63 billion in technology fees. Added to the technology fees secured at the end of last year for the drug’s approval in Europe, over KRW 100 billion in additional milestone payments are expected to be paid to the company. As a result,
- Company
- 'Brintellix', stable position in antidepressant drugs mkt
- by Eo, Yun-Ho Aug 7, 2025 06:05am
- 'Brintellix' has established a stable presence in the antidepressant drugs market over the past 10 years. Its presence has not been disturbed by issues such as generic entries. According to industry sources, Lundbeck Korea's Brintellix (vortioxetine) has been growing in the market for antidepressant drugs for the past 10 years. In Q1 2012
- Company
- COVID-19 vaccines transitioned to NIP
- by Whang, byung-woo Aug 6, 2025 06:10am
- COVID-19 vaccines, which were previously contracted through a pre-purchase model with pharmaceutical companies, will transition to the National Immunization Program (NIP) system. The Korea Disease Control and Prevention Agency (KDCA) announced on August 5 that it has signed a procurement contract for the supply of vaccines for the 2025-202
- Company
- Imfinzi wins nod as pre- and post-operative adjuvant therapy
- by Whang, byung-woo Aug 6, 2025 06:10am
- AstraZeneca announced on August 4 that it has received approval for its Imfinzi (durvalumab) as pre- and post-operative adjuvant therapy for patients with muscle-invasive bladder cancer from the Ministry of Food and Drug Safety on July 30. With this approval, Imfinzi has become the first and only immunotherapy in Korea to be approved for
